CBIO Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
-100.0%
1.0M
-90.4%
10.8M
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
-100.0%
1.0M
-90.4%
10.8M
0
0
Operating Expenses
26.4M
+2.3%
25.8M
-74.8%
102.3M
+295.3%
25.9M
+23.1%
21.0M
R&D
19.4M
+8.3%
17.9M
-81.2%
95.0M
+367.0%
20.3M
+68.4%
12.1M
SG&A
8.7M
+11.2%
7.9M
+7.6%
7.3M
+32.0%
5.5M
-38.1%
8.9M
Operating Income
-26364000
-6.6%
-24729000
+73.0%
-91492000
-253.5%
-25885000
-23.1%
-21030000
EBITDA
-26298000
-6.6%
-24665000
+73.0%
-91438000
-253.6%
-25857000
-23.0%
-21028000
Net Income
-24837000
-6.7%
-23283000
+74.8%
-92397000
-275.5%
-24607000
-12.9%
-21790000
EPS (Basic)
$-0.74
-5.7%
$-0.70
+82.3%
$-3.96
-211.8%
$-1.27
+74.2%
$-4.93
EPS (Diluted)
$-0.74
-5.7%
$-0.70
+82.3%
$-3.96
-211.8%
$-1.27
+74.2%
$-4.93
Shares (Diluted)
30.5M
+0.4%
30.4M
+48.4%
20.5M
+23.8%
16.5M
+328.9%
3.9M
Crescent Biopharma (CBIO) โ€” Financials